1. DECLARE-TIMI 58

2. SGLT2 Inhibitor CVOTs

3. DECLARE-TIMI 58 CVOT

4. DECLARE-TIMI 58 Key Baseline Characteristics

5. DECLARE-TIMI-58 Primary Endpoints

6. DECLARE-TIMI-58 Renal Composite Endpoint and HHF

7. DECLARE-TIMI 58 Key Safety Events

8. Clinical Implications

9. REDUCE-IT

10. REDUCE-IT CVOT

11. REDUCE-IT: Key Baseline Characteristics

12. REDUCE-IT: Primary Endpoint CV Death, MI, Stroke, Coronary Revasc, Unstable Angina

13. REDUCE-IT Treatment-Emergent Adverse Events

14. REDUCE-IT: Secondary Endpoint CV Death, MI, Stroke

15. Clinical Implications

16. CIRT

17. The Inflammatory Hypothesis of Atherosclerosis

18. JUPITER Trial

19. Effect of Low-Dose Methotrexate

20. CIRT Study Design and Key Baseline Characteristics

21. CIRT Results Part 1, at 8 Months

22. Inflammation Inhibition in the Absence of Lipid Lowers CV Event Rate

23. Tying It All Together

24. Published SGLT2 Inhibitor CVOT Study Cohorts

25. Published SGLT2 Inhibitor CVOTs Key Characteristics

26. Pooled Data for the Composite of MACE Myocardial Infarction, Stroke, and CV Death

27. Pooled Data for the Composite of MACE Stratified by ASCVD vs Multiple Risk Factors

28. ADA/EASD 2018 Consensus Report for Patients With Established ASCVD, HF, or CKD

29. Tying It All Together

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)